Bi-specific antibody therapy for the treatment of cancer

S Withoff; W Helfrich; LFMH de Leij; G Molema

Bi-specific antibody therapy for the treatment of cancer

S Withoff, W Helfrich, LFMH de Leij, G Molema^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

51 Citations (Scopus)

Abstract

Bi-specific antibodies (BsAbs) combine immune cell activation with tumor cell recognition as a result of which tumor cells are killed by pre-defined effector cells. In this review, a brief introduction to monoclonal antibodies will precede a more in-depth presentation of the current status of BsAb therapy for cancer. Target molecules and effector mechanisms aimed at tumor cells or aimed at tumor vasculature, and the application of recombinant DNA technology in the construction of antibodies, will be discussed. The lessons learned from the last decade will be discussed in consideration of the potential future development of BsAbs for cancer therapy.

Original language	English
Pages (from-to)	53-62
Number of pages	10
Journal	Current opinion in molecular therapeutics
Volume	3
Issue number	1
Publication status	Published - Feb-2001

Keywords

bi-specific antibodies
immunotherapy
recombinant antibodies
tumor antigen
CHAIN FV FRAGMENT
FC-ALPHA-RI
BISPECIFIC ANTIBODIES
T-CELLS
MONOCLONAL-ANTIBODIES
CD28 COSTIMULATION
TRANSGENIC MICE
PHASE-I
LYMPHOMA
BINDING

Handle.net

Persistent link

Cite this

@article{cc071e070d164e3b97a5014c3d07d3bd,

title = "Bi-specific antibody therapy for the treatment of cancer",

abstract = "Bi-specific antibodies (BsAbs) combine immune cell activation with tumor cell recognition as a result of which tumor cells are killed by pre-defined effector cells. In this review, a brief introduction to monoclonal antibodies will precede a more in-depth presentation of the current status of BsAb therapy for cancer. Target molecules and effector mechanisms aimed at tumor cells or aimed at tumor vasculature, and the application of recombinant DNA technology in the construction of antibodies, will be discussed. The lessons learned from the last decade will be discussed in consideration of the potential future development of BsAbs for cancer therapy.",

keywords = "bi-specific antibodies, immunotherapy, recombinant antibodies, tumor antigen, CHAIN FV FRAGMENT, FC-ALPHA-RI, BISPECIFIC ANTIBODIES, T-CELLS, MONOCLONAL-ANTIBODIES, CD28 COSTIMULATION, TRANSGENIC MICE, PHASE-I, LYMPHOMA, BINDING",

author = "S Withoff and W Helfrich and {de Leij}, LFMH and G Molema",

year = "2001",

month = feb,

language = "English",

volume = "3",

pages = "53--62",

journal = "Current opinion in molecular therapeutics",

issn = "1464-8431",

number = "1",

}

TY - JOUR

T1 - Bi-specific antibody therapy for the treatment of cancer

AU - Withoff, S

AU - Helfrich, W

AU - de Leij, LFMH

AU - Molema, G

PY - 2001/2

Y1 - 2001/2

N2 - Bi-specific antibodies (BsAbs) combine immune cell activation with tumor cell recognition as a result of which tumor cells are killed by pre-defined effector cells. In this review, a brief introduction to monoclonal antibodies will precede a more in-depth presentation of the current status of BsAb therapy for cancer. Target molecules and effector mechanisms aimed at tumor cells or aimed at tumor vasculature, and the application of recombinant DNA technology in the construction of antibodies, will be discussed. The lessons learned from the last decade will be discussed in consideration of the potential future development of BsAbs for cancer therapy.

AB - Bi-specific antibodies (BsAbs) combine immune cell activation with tumor cell recognition as a result of which tumor cells are killed by pre-defined effector cells. In this review, a brief introduction to monoclonal antibodies will precede a more in-depth presentation of the current status of BsAb therapy for cancer. Target molecules and effector mechanisms aimed at tumor cells or aimed at tumor vasculature, and the application of recombinant DNA technology in the construction of antibodies, will be discussed. The lessons learned from the last decade will be discussed in consideration of the potential future development of BsAbs for cancer therapy.

KW - bi-specific antibodies

KW - immunotherapy

KW - recombinant antibodies

KW - tumor antigen

KW - CHAIN FV FRAGMENT

KW - FC-ALPHA-RI

KW - BISPECIFIC ANTIBODIES

KW - T-CELLS

KW - MONOCLONAL-ANTIBODIES

KW - CD28 COSTIMULATION

KW - TRANSGENIC MICE

KW - PHASE-I

KW - LYMPHOMA

KW - BINDING

M3 - Article

SN - 1464-8431

VL - 3

SP - 53

EP - 62

JO - Current opinion in molecular therapeutics

JF - Current opinion in molecular therapeutics

IS - 1

ER -

Bi-specific antibody therapy for the treatment of cancer

Abstract

Keywords

Handle.net

Fingerprint

Cite this